Enhancing the QUAlity and Transparency Of health Research
Search for reporting guidelines
Use your browser's Back button to return to your search results
EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology
| Reporting guideline provided for? (i.e. exactly what the authors state in the paper) |
Reporting comparative effectiveness research using observational data in rheumatology |
| Full bibliographic reference | Courvoisier DS, Lauper K, Kedra J, de Wit M, Fautrel B, Frisell T, Hyrich KL, Iannone F, Machado PM, Ørnbjerg LM, Rotar Z, Santos MJ, Stamm TA, Stones SR, Strangfeld A, Bergstra SA, Landewé RBM, Finckh A. EULAR points to consider when analysing and reporting comparative effectiveness research using observational data in rheumatology. Ann Rheum Dis. 2022;81(6):780-785. |
| Language | English |
| PubMed ID | 35058229 |
| Relevant URLs (full-text if available) |
Read the full-text of this reporting guideline. |
| Study design | Observational studies |
| Clinical area | Rheumatology |
| Applies to the whole report or to individual sections of the report? | Data, Harms/adverse effects/safety data, Procedure/Method, Statistical methods and analyses, Study characteristics (participants etc.) |
| Record last updated on | May 17, 2022 |